Keros Therapeutics

General Information


We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. We are a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. We have leveraged this understanding and developed a discovery approach to generate large and small molecules to address diseases of these tissues.

Employees: 23
Founded: 2015
Contact Information
Address 99 Hayden Avenue, Suite 120, Building E, Lexington, MA 02421, US
Phone Number (617) 314-6297
Web Address
View Prospectus: Keros Therapeutics
Financial Information
Market Cap $302.0mil
Revenues $0.01 mil (last 12 months)
Net Income $-14.1 mil (last 12 months)
IPO Profile
Symbol KROS
Exchange NASDAQ
Shares (millions): 6.0
Price range $16.00 - $16.00
Est. $ Volume $96.0 mil
Manager / Joint Managers Jefferies/ SVB Leerink/ Piper Sandler
CO-Managers H.C. Wainwright & Co.
Expected To Trade: 4/8/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change